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Summary.-Two 3-methylcholanthrene and a spontaneous BALB/c fibrosarcoma
were examined for tumour-associated antigens (TAA) by in vivoand invitroinduction
of tumour-immune responses. When BALB/c mice were immunized to these fibro-
sarcomas by surgical tumour removal, cross-reacting tumour-associated trans-
plantation antigens (TATA) were detected on all 3 tumours. Cytotoxic effector cells
(CL) were then induced in vitrobyco-culture ofBALB/cspleencellswiththe spontan-
eous, or one of the carcinogen-induced fibrosarcomas. These CL were shown to be
cytotoxic T cells (Tc) and to be directed against cross-reacting TAA on all3 tumours,
by two in vitro 51Cr-release assay systems, direct 51Cr-release cytotoxicity and
cellular competitive inhibition of51Cr release. Further studies demonstrated that the
fibrosarcoma TAA involved in in vitro induction of Tc were not present on normal
adult or foetal tissues. A secondary cytotoxic response was also detected in vitro
when spleen cells from mice immunized to a carcinogen-induced fibrosarcoma
were tested. The patterns of cross-reactivity detected by the in vivo and primary in
vitro tumour-immune responses suggested that the TAA detected in vivo (TATA)
were not identical to the TAA detected in vitro.
THE first conclusive demonstration that
tumours expressed specific tumour-asso-
ciated antigens (TAA) was performed by
Gross in 1943, using a 3 methylcholan-
threne induced C3H murine sarcoma. Sub-
sequent experimentation in highly inbred
laboratory animals has firmly established
the concept of TAA and, in particular, of
"unique" tumour-associated transplanta-
tion antigens (TATA) on chemically
induced tumours (Foley, 1953; Prehn and
Main, 1957; Klein et al., 1960; Old et al.,
1962). In vivo studies with chemically
induced tumours in the ensuing years
have generally confirmed these observa-
tions (Baldwin, 1973; Wahl et al., 1974;
Forbes, Nakao and Smith, 1975; Fritze
et al., 1976). However, in a few studies,
shared TATA on chemically induced
tumours have also been demonstrated
(Koldovsky and Svoboda, 1963; Reiner
and Southam, 1967; Robert, 0th and
Dumont, 1973).
The introduction of in vitro methods
for the study of TAA has, however,
revealed a widespread sharing of TAA
among chemically induced tumours. Cross-
reacting TAA have been detected in vitro
both by serological techniques (Harder
and McKhann, 1968; Hellstrom, Hell-
strom and Pierce, 1968; Tachibana and
Klein, 1970; Burdick and Wells, 1973;
Fritze et at., 1976) and by assays of cell-
mediated immunity where lymphoid cells
from tumour-bearing or tumour-immune
hosts were tested against various tumour
cell lines (Hellstrom et al., 1968; Takasugi
and Klein, 1970; Bataillon, Ross and
Klein, 1975; Forbes et al., 1975; Whitney,
Levy and Smith, 1975).
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The in vivo specificity of immunity to
chemically induced tumours has been
ascribed to the immunization ofT lympho-
cytes by "unique" TATA (Rollinghoff and
Warner, 1973; Kearney, Basten and
Nelson, 1975; Whitney et al., 1975). The
invitro cross-reactivity ofimmunity, onthe
other hand, has been shown to vary both
with the source of the effector cell
(Bataillon et al., 1975) and with the timing
of cell harvest after immunization
(Kearney et al., 1975). The introduction of
wholly in vitro methods for the induction
and assay of tumour-specific immunity
has provided another means of examining
the TAA antigens of chemically induced
tumours. McKhann and Jagarlamoody
reported in 1971 the successful in vitro
immunization of C3H spleen cells against
2 C3H 3-methylcholanthrene-induced
fibrosarcomas. The immune lymphocytes
(CL) were assayed both in vitro, on 3H-
thymidine-labelled fibrosarcoma cells, and
also in vivo in Winn-type assays (Klein
et al., 1960; Winn, 1961) where CL ad-
mixed with tumour cells were inoculated
into syngeneic mice. The in vivo Winn
assay results showed clear-cut specificity
ofin vitro immunization to "unique" TAA
on each of the tumours, but the in vitro
3H-thymidine-release assay with the same
CL demonstrated some cross-reactivity
between the 2 fibrosarcomas. Subsequent
studies have confirmed the in vitro
immunization of lymphocytes by TAA on
carcinogen-induced tumours (Warnatz and
Scheiffarth, 1974; Small and Trainin,
1975; Kall and Hellstrom, 1975). However,
conflicting results have emerged from
these in vitro experiments, with claims
both that the specificity of the in vitro
tumour specific immunity induced is to
unique TAA alone (McKhann and Jagarla-
moody, 1971; Kall, Hellstrom and Hell-
strom, 1976) and that it is to both cross-
reacting and unique TAA on the same
tumour cells (Warnatz and Scheiffarth,
1974). The identity of the effector cyto-
toxic cells in these in vitro systems was
not described.
This paper presents our experience
with both in vitro and in vivo induction of
tumour-specific immunity to 3 BALB/c
fibrosarcomas, with particular reference
to the TAA involved. Also included is
data which indicates that the in vitro
cytotoxic cell is a T lymphocyte.
MATERIALS AND METHODS
Media.-Eagle's minimal essential medium
with non-essential amino acids (Grand Island
Biological Co., NY) was used supplemented
with 10% foetal calf serum (FCS) (Common-
wealth Serum Laboratories) 100 u/ml of
penicillin, 100 iig/ml of streptomycin and
buffered with sodium bicarbonate (MEMF).
The medium was prepared fresh each day,
and 2-mercaptoethanol (2ME) was added to
a final concentration of 10-4M. The assay was
performed in Dulbecco's modified Eagle's
medium (Commonwealth Serum Laboratories,
Melbourne, Australia) supplemented with
10% FCS (DMEF).
Animals.-Inbred male mice, aged 6-10
weeks, from the Hall Institute BALB/c An/
Bradley/WEHI specific-pathogen-free colony,
were used throughout this study.
Tumours.-Three BALB/c fibrosarcomas
were used in this study, and were adapted to
tissue culture early in their transplantation
history. WEHI-164 and WEHI-167 are 3-
methylcholanthrene-induced BALB/c fibro-
sarcomas whose origins and adaptation to
tissue culture have been described previously
(Rollinghoff and Warner, 1973). WEHI-1l is
a BALB/c fibrosarcoma which arose spon-
taneously, and was adapted to tissue culture
by a technique described previously (Rolling-
hoff and Warner, 1973). The tissue-culture
lines of WEHI-164 and WEHI-1l were used
for all the in vitro experiments involving these
2 tumours, whereas in the in vivo experiments
the immunizations were performed with in
vivo-derived cells, and the tumour challenge
with either in vivo- or in vitro-derived cells.
WEHI-167, however, proved difficult to
maintain in tissue culture, and was therefore
inoculated into BALB/c mice and maintained
in serial passage in vivo. The WEHI-167
tumour cells used in this study were derived
from cell suspensions prepared from in vivo
tumours according to the method of von
Boehmer and Shortman (1973). This tech-
nique removes dead cells and cellular debris
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from the suspension, leaving a single-cell
tumour suspension of over 80% viability as
determined by eosin dye exclusion. EL-4,
a C57BL T lymphoma maintained in tissue
culture, was used for the demonstration of
specificity in the inhibition assay, and was
kindly provided by Dr Alan Harris.
Invivoimmunization.-The3 fibrosarcomas
were tested for the presence of TATA in
BALB/c mice by the technique of surgical
tumour removal as previously described
(Rollinghoff, Rouse andWarner, 1973; Burton
and Warner, 1976). Briefly, the minimum
tumour dose (MTD) of viable tumour cells
capable of initiating lethal tumour growth
in 100% of inoculated BALB/c mice was
determined for each tumour. Groups of
BALB/c mice were then injected in the right
hind leg with a dose in excess of this, and the
legs amputated under ether anaesthesia when
the tumour became palpable. Two weeks later
these mice were challenged, together with
age- and sex-matched BALB/c controls, s.c.
on the right flank with the MTD of the
immunizing tumour. The mice were then
observed 2-3 times weekly and the tumour
diameters determined by taking the mean of
2 transverse measurements of the tumour
mass.
In the cross-immunity experiments, twice
as many BALB/c mice were immunized by
this procedure, and half challenged with the
MTD of the immunizing tumour, and half
with the MTD of the tumour being tested for
cross immunity.
In vitro induction and assay of tumour-
specific immnunity.-The techniques have
been previously described in detail, and so
are only outlined here.
Induction procedure (Burton, Thompson
and Warner, 1975).-Square 100mm tissue-
culture trays partitioned into 25 compart-
ments (Sterilin Ltd, Richmond, Surrey,
England) were used. Varying numbers of
irradiated (5000 rad) stimulator fibrosarcoma
cells, in a volume of 0-1 ml, were placed into
the compartments and 3-6 ml of MEMF
added. Then 15 x 106 viable nucleated
responder BALB/c spleen cells (in 0-2 ml)
were added to each compartment, and the
trays placed in a humidified incubator at
37°C in 10% CO2 in air for 5 days; these
conditions being optimal for the induction
of tumour-specific immunity. This method
was adopted in order to produce responder/
stimulator curves for the various in vitro
direct cytotoxicity experiments. Groups of 10
identical compartments were set up for each
ratio, and stimulator cell numbers, in the
range of 1-5 X 102-1-5 x 105 per compart-
ment, were used. In addition, irradiated
(5000 rad) C57BL stimulator spleen cells
were used to alloimmunize BALB/c respon-
der lymphocytes in vitro by culturing the 2
cell types together as described above, but at
a responder/stimulator (R/S) ratio of 10/1.
BALB/c responder spleen cells alone or with
1-5 x 106 irradiated (5000 rad) syngeneic
stimulator BALB/c spleen cells.
At the end of the incubation period the
cultured cells were harvested, pelleted by
light centrifugation, identical CL lots pooled,
and resuspended in fresh DMEF. They were
then further incubated in 35mm Petri dishes
for 21 h, as this resultsina2-3-foldaugmenta-
tion of lytic activity. Finally they were
harvested and a viable cytotoxic effector cell
(CL) count was performed by eosin dye
exclusion.
Direct 51Cr-release cytotoxic assay (Burton
et al., 1975).-This was performed in quadru-
plicate in microtitre trays (Micro Test II
Tissue Culture Plate, Falcon Plastics, Ox-
nard, California). Fibrosarcoma tissue-culture
cells were labelled with 51Cr. Background
release of 5ICr was determined by incubating
25 x 103 ofthese labelled tumour target cells
in 200 ,ul of DMEF. The maximal amount of
51Cr releasable from the targets was assessed
by lysing aliquots of 12-5 x 103 labelled
target cells in 200 ,ul of Zaponin (improved
lysory agent for white blood cell counts,
Coulter Electronics Ltd, Dunstable, Beds.,
UK) in distilled water. The test assays were
made at CL/target (CL/T) ratios of 100:1,
50:1 and 25:1. Thus 25 x 105, 12-5 x 105
and 6-25 x 106 CL in 100 ,u of DMEF were
dispensed into wells and then 25 x 103
labelled tumourtarget cells in 100 ,ul ofDMEF
were added.
The standard assay time was 4 h at 37°C
followed by an additional hour at 45°C to
facilitate the release of 5ICr from the lysed
tumour target cells. Then 100 ,ul of super-
natant was removed from each of the back-
ground and test assay wells, while from the
Zaponin dilution wells 100lO aliquots from
2 wells were pooled, since each well con-
tained half the number of targets. These
samples were counted on a Beckman Bio-
gamma scintillation counter, and the per-
cent specific lysis computed as
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Percentage specific lysis=
test count-background count X 100
maximal count-background count
Inhibition assay (Chism, Burton and
Warner, 1976).-The CL were first added
(25 x 105 in 50 pu) to the test well of the
microtitre tray, followed by varying numbers
(in 50 y1) of unlabelled inhibitor cell prepara-
tions (blocker cells) and then the 51Cr-labelled
tumour target cells (25 x 103 in 100 pi). The
assay conditions were then as described
above for direct lysis. Control tubes assessed
specific lysis in the absence of blocker cells,
and the results were expressed as percent
inhibition of specific lysis. In all these studies
the absolute number of CL and 51Cr target
cells remained constant, only the blocker-cell
number was varied, and this is given in the
test figures as a blocker/target cell ratio.
Percentage inhibition of specific lysis=
control lysis-test lysis 100
control lysis
Blocker cells included the 3 fibrosarcomas,
EL-4, adult BALB/c viable nucleated spleen
cells, and 14-day viable nucleated BALB/c
foetal liver cells. The foetal-cell suspension
was prepared according to a technique
described previously (Chism et al., 1976).
Anti-Thy-1.2 treatment.-Anti-Thy-1.2 sera
was prepared and supplied by Ms J. Gamble.
Its mode of production, cytotoxic titre and
specificity for T cells have been described in
detail (Burton, Chism and Warner, 1976).
In vitro-induced CL were treated with the
serum at a dilution of 1:3 for 30 min at
37°C, after which they were resuspended in a
1:6 dilution of agarose-absorbed guinea-pig
complement for a further 30 min at 37°C.
The CL were then counted and made up to
25 + 106/ml in DMEF for the assay.
°0 VCC-
total viable CL after treatment
total viable CL before treatment
RESULTS
Cross immunity between fibrosarcomas in
vivo
The technique of surgical tumour re-
section proved a reliable method for
inducing tumour immunity in vivo (Table
I). The use of the MTD for the challenge
dose of a particular tumour allowed a
clear demonstration of immunity to that
tumour. Each particular tumour immun-
ization and challenge combination was
performed at least 3 times, and the results
presented are from representative experi-
ments. The first 2 lines of each section of
the Table show the result of attempts to
demonstrate TATA onthe 3 fibrosarcomas.
Both WEHI-164 and WEHI-ll regularly
elicited tumour-specific immunity in the
strain of origin, and in both cases there
was a significant difference in the growth
rate between the immunized and control
mice when both groups were challenged
with the MTD of the immunizing
tumour (P<0 01, Student's t test). Fur-
thermore, 50o of the mice in the
groups immunized by surgical tumour
removal to either of these tumours
survived a challenge with the MTD of the
relevant tumour, while there were no
survivors in the control groups. WEHI-
167, on the other hand, did not effectively
immunize BALB/c mice against itself.
There was no difference in the growth
rate of this tumour between the mice who
underwent a surgical tumour removal of
WEHI-167 and the control mice, in any
of the 5 experiments. In the example
shown there was one survivor in the
treated group, and the general finding was
that survivors also were rare when mice
who had undergone resection of WEHI-
167 were challenged with the MTD of the
tumour. Mice immunized with WEHI-164
cells do not show any significant degree of
immunityto challengewith atissue culture
line of a plasmacytoma (MPC-11) indicat-
ing that cell-bound foetal calf serum anti-
gens are probably not involved in the
immunity demonstrated in Table I.
The cross-immunity experiments, how-
ever, produced some unexpected findings.
In the first instance, there was strong
cross immunity between WEHI-11 and
WEHI-164, indicating a highly immuno-
genic shared TATA. Although readily
detectable in reciprocal immunization and
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TABLE I. Cro88 Immunity in vivo between 3 BALB/c Fibrosarconas
Tumour growth:
Immunizing No. (mean diam.
tumour* No. mice Challenge tumour survivorst (mm) i s.e.)
WEHI-164 14 WEHI-164 6 5 L 2
Nil§ 9 WEHI-164 0 19 i1
WEHI-164 6 WEHI-11 2 9 ± 3
Nil 9 WEHI-11 0 16+ 2
WEHI-164 7 WEHI-167 0 14 i1
Nil 5 WEHI-167 0 14 4- 1
WEHI-11
Nil
WEHI-11
Nil
WEHI-11
Nil
WEHI-167
Nil
WEHI-167
Nil
WEHI- 167
Nil
12
9
7
4
6
10
15
17
4
7
12
13
WEHI-11
WEHI-11
WEHI-164
WEHI-164
WEHI-167
WEHI-167
WEHI-167
WEHI-167
WEHI-164
WEHI-164
WEHI-11
WEHI-11
7
0
4
0
1
1
0
0
5
0
* Mice preimmunized by surgical tumour removal.
t Mice surviving tumour-free longer than 6 weeks.
I Subcutaneous tumour growth as recorded at a particular time (2-
§ Age-sex-matched non-immunizedl mice (controls).
challenge experiments, it was best demon-
strated when BALB/c mice were immun-
ized to WEHI-11 and challenged with
WEHI-164. In that case the survival rate
of the immunized mice was over 5000 and
the difference in growth rates particularly
marked (P<0 01, Student's t test). The
reverse situation, immunized with WEHI-
164 and challenged with WEHI-I1, pro-
duced fewer survivors (330%) but there was
still a highly significant difference in
growth rates (P<0*01, Student's t test).
When similar experiments were per-
formed with WEH-1i67, a further un-
expected, but readily repeatable, result
occurred. For, although mice immunized
to WEHI-164 and WEHI-I 1 failed to
reject WEHI-167, a result we had
expected on the basis of the failure of
WEHI-167 to immunize against itself,
mice immunized to WEHI-167 regularly
rejected WEHI-11. Survival rates of50%o were common when mice immunized by
surgical tumour removal to WEHI-167
were challenged with WEHI- 11, and there
was always a significant difference in
growth rates between immunized and
control mice (P<0*01, Student's t test).
4 ± 2
12 - 3
2 ± 2
19 ± 1
16 ± 3
17 ± 4
15 ± 6
18 ± 4
11 ± 1
11 4- 6
9 ± 8
17 +4
-3 weeks) after inoculation.
For WEHI-164, in contrast, there was the
expected result, and mice treated by a
surgical resection of WEHI-167 showed
no detectable immunity to WEHI-164.
This readily demonstrable cross reactivity
in vivo emphasizes the need carefully to
ascertain the MTD of a particular tumour
in the mouse strain under investigation.
Immunity due to TATA is much weaker
than immunity due to histocompatibility
antigens, and is easily overcome by large
tumour inocula (Klein et al., 1960).
Cross immunity between fibrosarcomas in
vitro: cytotoxicity studies
When BALB/c spleen cells are cultured
under the in vitro conditions described,
either alone or with varying numbers
of irradiated syngeneic spleen cells,
cytotoxic effector cells are induced.
This phenomenon has been termed "auto-
sensitization in vitro" (Cohen, Globerson,
and Feldman, 1971; Ilfeld et al., 1973;
Ilfeld, Carnaud, and Klein, 1975). Wehave
extensively investigated this phenomenon
(Burton, Chism and Warner, 1977) and so
only include here illustrative data relevant
to the fibrosarcomas (Table II). Here it
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II. Comparison of in vitro "Auto- than the "'autosensitized" CL for the
itized" and Tumour-specific Cyto- tumour target. Similar experiments with
Lymphocytes (Responder Spleen WEHI-] 1 as the target did not detect
i, BALB/c) any cytotoxicity by "autosensitized" CL
AMean 0o specific on this target. ator* lysis 4- s.e. The cytotoxicity assays were set up at Is No. of (CL/T 1U001) CL/T ratios of 100/1, 50/1 and 25/1. Three rad) expts. 5ICr WEHI2164 t such experiments are shown in Fig. 1 and,
37 21t6 ± 2-6
14 54 17-5 + 1-5 0 24 as can be seen, the CL/T curve is linear in
164 22 29-5 --:3 1 0 008 a semi-log plot. Therefore, in general, only
pondter/stimulator ratio 1000/1 for BALB/c CL/T ratios of 100/1 are reported for the Lcecl in vitro to WEHI-164 andl 10/1 for the cytotoxicitv experiments, and in the
risi1tized" CL.
dlues by MIann Whitney U test between the inhibition assays the CL/T employed was NIL group an(d the other two groups. 100/1, unless otherwise indicated.
The results of the in vitro experiments
With tlh- + R fihr( ,rccm .vP_q,IPd 1 ,m1n- ,
complete in vitro cross reactivity of TAA
bel,%iaroan ftham Tn f.ho fI~ro-. i-noA-nan +bhic L* UUWUU1I LIIU111I. III UII U i LI I: i UIIU U111i
was demonstrated by direct cytotoxicity
experiments with WEHI-164 and WEHI-
I 1. BALB/c CL induced in vitro to WEHI-
164 lysed both 51Cr-labelled WEHI-] 64
and 51Cr-labelled WEHI-1l, with the peak
response to WEHI-164 at an R/S ratio of
1000/1 (Fig. 2). A similar finding occurred
when BALB/c CL were induced in vitro
to WEHI-il (Fig. 3). Both 51Cr-labelled
tumour targets, WEHI-11 and WEHI-
164, were lysed. The peak R/S ratio,
however, was 10-30-fold higher. In both
cases the specific lysis of WEEHI-1i was
significantly less than that of WEHI-164
25/1 50/I 100/1 (PA<0U1, Student's t test, peak values). CL/T This probably reflects a difference in the
.The lines are the CL/T curves ob- rate of 51Cr- release from the 2 tumours
e(lwhen BALB/c CL induced in vitro
vVEHI-164 at an R/S ratio of 1000/1 as the inhibition experiments indicated
- assayed on 51Cr WEHI-164 over the that there was not likely to be a significant
!Y0 of CL/T ratios shown. ;e of CL/T ratios shown, qualitative difference in TAA expression,
and it has been shown that the kinetics of
seen that BALB/c spleen cells 51Cr release after target cell lysis by CL
significant cytotoxicity for 51Cr- do vary with the cell line (Sanderson,
I WEHI-164 when they are cul- 1976).
lone, or with irradiated BALB/c On the basis of these experiments, R/S
cells at a R/S ratio of 10/1. There is ratios of 10,000/1 for WEHI-li were
ificant difference in the cytotoxicity chosen as optimal for the induction of CL.
ctetectect between these two induction
modes. However the in vitro induction of
tumour-immune CL from the same spleen
cell pools against WEHI-164 at the
optimal R/S ratio (1000/1) resulted in CL
that were significantly more cytotoxic
Cross immunity between fibrosarcomas in
vitro: inhibition studies
W"hen BALB/c CL were induced in
vitro to WEHI-164 and assayed on the
same 51Cr-labelled fibrosarcoma, WEHI-
TABLE
sens
toxic
Cellb
Stimulb
cell
(5000
NIL
BALB/c
WEHI-]
* Res1
CL indu
"autoser
tP vP
BALB/c
4U
30
Ln
-
Q. 20
Ln
4.-
z
Li
u
cc
0-
IC
Fi(c. 1
tain
to X
were
rang
can be
develor
labellec
tured o
spleen
no sign]
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7-1
7-,
711
I--,' I
100/1 1000/1
RESPONDER/STIMULATOR
K,OOO 100,000/I
FIG. 2.-BALB/C responder spleen cells (15 x 166) were immunize(d in vitro with varying numbers of
WEHI-164 stimulator cells, and the CL indluced assayed on 5ICr-labelled WEHI-164, 0 O,
and WEHI-I 0--0, at a CL/T ratio of lOO/l.
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FIG. 3. BALB/c responder spleen cells (15 x 106) were immunized in, vitro with varying numbers of
WEHI-1 stimulator cells, and the CL induced assayed on 5lCr-labelled WEHI-164, * *,
and WEHI-1I 0- 0, at a CL/T ratio of 100/1.
164 and WEHI-i both inhibited lysis of
the labelled target cell to the same extent
(Fig. 4(a)). Normal adult BALB/c spleen
cells did not inhibit lysis significantly,
indicating that the antigens involved were
not present on this normal tissue. In the
corresponding experiment in which un-
labelled WEHI-164 and WEHI 11 were
added to BALB/c CL induced in vitro to
WEHI-1l, and 51Cr-labelled WEHI-11,
there was a similar result. Both fibro-
sarcomas caused comparable high levels
of inhibition over the blocker/target ratio
range employed (Fig. 4(b)). In this
second experiment, in addition to the
normal spleen-cell control, viable 14-day
BALB/c foetal liver cells were also added
over the blocker/target ratio range shown.
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B
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o-- -- ---o
0 10/1 20/1 40/1 80/1 0 10/1 20/1 40/1 80/1
BLOCKER/TARGET RATIO
FIG. 4(a). The inhibition curves obtained when varying numbers of unlabelled blocker WEHI-164
(0 0) and WEHI-11 (0 -O) tumour cells, respectively, were added to the assay of
BALB/c CL, induced in vitro with WEHI-164, and 51Cr-labelled WEHI-164 (CL/T ratio of 100/1).
The line A--A is the corresponding cturve when adult BALB/c nuicleated viable spleen cells
were added at the blocker/target ratios shown.
FIG. 4(b). The inhibition curves obtained when varying numbers of unlabelled blocker WEHI-164
(0 0) and WEHI-11 (0 --- O) tumour cells, respectively, were added to the assay of
BALB/c CL, induced in vitro with WEHI-11 and 51Cr labelled WEHI-11 (CL/T ratio of 100/1).
The liines - A- and A- -A are the inhibition curves obtained when viable nucleated adult
BALB/c spleen and 14-day BALB/C foetal liver cells, respectively, were addedl to the same assay
at the blocker/target ratios shown.
However, as with the adult spleen cells,
there were no significant inhibition of
lysis. These results indicate that WEHI-
164 and WEHI-lI share TAA as detected
by these in vitro techniques, and hence
confirm both the in vivo and direct in
vitro cytotoxicity experiments. Further-
more they also indicate that the TAA
detected are not oncofoetal or selfantigens.
The final inhibition experiment was
performed over a different range of
blocker/target ratios, and also included
WEHI-167, prepared from an in vivo
tumour as described earlier. In this
experiment all 3 fibrosarcomas, WEHI-
164, WEHI-167 and WEHI-11, caused
significant inhibition of the lysis of 51Cr-
labelled WEHI-164 by BALB/c CL
induced in vitro to that tumour (Fig. 5).
Furthermore, over this range of blocker!
target ratios, differences in inhibition
between the 3 tumours were apparent.
For, although all 3 caused 100% inhibi-
tion at a blocker/target ratio of 30/1,
indicating that there was no significant
qualitative difference in TAA expression,
there were significant differences in inhibi-
tion at the 3/1 blocker/target ratio. Here
WEHI-164 caused 70%0 inhibition, but
WEHI-11 only 30%0 (P<0O01 Student's t
test) which indicates a significant quanti-
tative difference in TAA expression on
these 2 tumours. It is notable that WEHI-
167 is not significantly different from
WEHI-164 in this respect. Again, neither
14 day BALB/c foetal liver or normal
BALB/c spleen cells caused significant
inhibition, further indicating that the
antigens involved are not present on these
adult and foetal tissues.
The inhibition assay thus complements
the direct cytotoxicity assay in the
determination of the specificity of CL.
However, it has a number of limitations,
which we have investigated in depth
(Chism et al., 1977). These include non-
specific inhibition, which is particularly
troublesome with large tumour cells at
high blocker/target ratios. For the pur
poses of this paper, an inhibition assay
which demonstrates that WEHI-164, the
largest of the cell lines used, does not
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FIG. 5.-The lines 0 0, x-- x and
+-- + are the inhibition curves ob-
tained when varying numbers of unlabelled
blockerWEHI-164, WEHI-167 andWEHI-
11 tumour cells, respectively, were added
to the assay of BALB/c CL, induced in
vitro with WEHI-164, and 5lCr-labelled
WEHI-164 (CL/T ratio of 100/1). The
lines A--- A and A--, are the
corresponding curves obtained when
viable nucleated BALB/c spleen and 14-
day BALB/c foetal liver cells were added
to the same assay at the blocker/target
ratios shown.
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FiG. 6. The inhibition curves obtaine(l
when varying numbers of unlabelled
blocker EL-4 (0 0) and WEHI-164
(0--O) tumour cells were added to the
assay of BALB/c CL, incluce(1 in vitro to
C57BL spleen cells, and "Cr-labelled EL-4
(CL/T ratio of 20/1).
inhibit non-specifically at blocker/target
ratios of 20/1 or less is included (Fig. 6).
When BALB/c are induced in vitro to
C57BL alloantigens they lyse the 51Cr-
labelled C57BL T lymphoma EL-4 in
vitro. When unlabelled EL-4 and WEHI-
164 tumour cells are used as blockers it
can be seen that EL-4 can totally inhibit
lysis of the target cell, and also that
WEHI-164 does not inhibit lysis over the
blocker/target ratio range of 5/1 to 20/1.
Identity of the CL induced in vitro
The CL induced in vitro both to murine
'I oncofoetal and plasmacytoma TAA
(Rollinghoff and Wagner, 1973; Burton
et al., 1976) have been shown to be T
lymphocytes. When CL induced in vitro
to WEHI-164 were treated with anti-
TABLE III. Identity of the CL induced in
BALB/c in vitro to WEHI-164 (R/S_
1000/1)
Treatment
Nil
Complement (C1)
Anti Thy-1.2
Anti Thy-1.2 + Cl
* Viable cell count.
°' VCC*
100
82
79
28
Mean % specific
lysis s.e.
(CL/T 100/1) 5lCr WEHI-164
19 ± 1
22 -1- 1
14 1
3
± 2
Thy-1.2 serum and complement (Table
III) cytotoxicity was almost totally abrogated, indicating that the cytotoxicity in this system is virtually all mediated by T cells.
Secondary cytotoxic tumour-immune res-
sponse in vitro to WVEHI-164
It has previously been demonstrated
that spleen cells from mice immunized
in vitro to a syngeneic plasmacytoma can
be induced to undergo a secondary cyto- toxic tumour response in vitro (Rolling- hoff, 1974) and a recent report indicates
a similar secondary response to murine
sarcomas (Kall et al., 1976). A group of
age- and sex-matched BALB/c mice was
taken and half the group immunized to
WEHI-164 by surgical tumour resection.
Four weeks later spleen cells were harvest-
ed from the immune and non-immune
mice and cultured with irradiated WEHI-
(A
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o 60
g 40
z
Z 20-
U
Q. t
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-
-
%_
c. I
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Mean 0° specific
lysis ± s.e.
(CL/T = 100/1)
5lCr WEHI-164
BALB/c 19 -2 1+
BALB/c immunet to
WEHI-164 35 ± 1.
* Responder/stimulator = 1000/1.
t Mice irnmunized by surgical tuimour removal.
t P<0 01, Student's t test.
164 in vitro at R/S 1000/1. The CL
induced were assayed on 51Cr WEHI-1 64,
and it can be seen (Table IV) that the
cytotoxicity detected in the CL induced
from immune mice was about twice that
of the non-immune mice. These results
confirm that spleen cells from mice
immune to fibrosarcomas, like those from
mice immune to plasmacytomas, undergo
a secondary cytotoxic response in vitro.
DISCUSSION
The data presented herein indicate that
spontaneous and carcinogen-induced fibro-
sarcomas can be immunogenic both in
vivo and in vitro. It has been demonstrated
in vivo that the antigenicity of carcinogen-
induced tumours can be correlated with
the duration of the latent period and dose
of carcinogen used in the induction proto-
col (Prehn, 1975). Tumours that appear
rapidly after a high dose of carcinogen
are more immunogenic than those that
arise a long time after a small dose.
Furthermore, it has also been shown that
spontaneous malignant neoplasms of mice
may, in general, be non-immunogenic
(Hewitt, Blake and Walder, 1976). How-
ever, WEHI-I1 , a spontaneous fibro-
sarcoma which arose in a BALB/c mouse,
had TATA detectable in vivo and also
expressed TAA in vitro. Furthermore,
these tumour antigens were shared with
2 other carcinogen-induced fibrosarcomas.
As reviewed herein, cross-reacting
tumour antigens lhave been detected on
murine fibrosarcomas by both in vivo
and in vitro techniques. When CL are
induced in vitro to fibrosarcoma antigens
it has been claimed that unique TAA
dominate the response (McKhann and
Jagarlamoody, 1971; Warnatz and Scheif-
farth, 1974; Kall and Hellstrom, 1975;
Kall et al., 1976). However, in the studies
presented herein, cross-reacting TAA were
the major antigens detected, both in vivo
and in vitro. Furthermore there is evidence
that these techniques detect a hetero-
geneity of fibrosarcoma TAA. At least
2 cross-reacting TATA were detected in
vivo, one expressed on both WEHI- 1I
and WEHI-164, and one expressed on
WEHI-167 and WEHI-11. WEHI-167
grew equally well in mice immunized to
any of the fibrosarcomas as in control
mice; however, it did immunize mice to a
shared TATA as detected by challenge
with WEHI-11. This result illustrates a
major paradox of tumour immunity,
where despite the detection of TAA on
many tumours a fatal outcome usually
ensues for the host. A tumour may readily
induce an immune response but be
resistant to the effector immune mecha-
nism. The ability of a tumour to immunize
against shared TATA but grow just as
rapidly in immune and non-immune mice
has been reported for murine plasmacyto-
mas (Burton and Warner, 1976). These
in vivo results exemplify the need carefully
to titrate tumours in the strain of origin,
so that too large a challenge dose is not
used.
The results of the in vitro induction of
cytotoxic lymphocytes to these fibro-
sarcomas has demonstrated a complete
sharing ofantigens between the 3 tumours.
The response as revealed by anti-Thy-1.2
serum treatment, is completely mediated
by cytotoxic T lymphocytes, as was found
for the in vivo response to the fibrosarcoma
WEHI-164 (Rollinghoff and XVarner,
1973). Since all 3 tumours completely
inhibited the cytotoxic activity directed
against one of them, a common antigenic
determinant is involved. The degree of
TABLE IV.-Secondary Cytotoxic Res-
ponse in vitro to WEHI-164 (Stimu-
lator Tumour Cells; JITEHI-164
(5000 rad))
Responder spleen
cells*
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inhibition observed atblocker/target ratios
of less than 30/1 is due to specific inhibi-
tion and not to the non-specific inhibition
observed by these tumours at higher
ratios (Fig. 6). The nature of this common
antigenic determinant has not been fully
defined, but is clearly shown to be distinct
from the oncofoetal antigens also expres-
sed by these tumours (Chism et al., 1976)
since foetal liver shows no significant
blocking in this system, whereas it does so
in the OFA studies (Chism et al., 1976).
The possibility that sensitization to foetal
calf serum components is involved has
been discussed elsewhere in detail (Burton
et al., 1977) but is not the explanation
for this common antigen, since the WEHI-
167 cells were derived from in vivo tumour,
not from a cultured line.
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